ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer

被引:0
作者
Ma, Bo [1 ,2 ]
Ma, Qianqian [2 ]
Jin, Chunhui [3 ]
Wang, Xiaohong [1 ]
Zhang, Guolei [1 ]
Zhang, Huiying [1 ]
Seeger, Harald [2 ]
Mueck, Alfred O. [2 ]
机构
[1] Huzhou Teachers Coll, Affiliated Cent Hosp, Huzhou 313000, Zhejiang, Peoples R China
[2] Univ Hosp, Tubingen, Germany
[3] Wuxi Hosp Tradit Chinese Med, Wuxi, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY | 2015年 / 8卷 / 10期
关键词
ADAM12; clinical outcome; estrogen receptor; breast cancer; REGULATED EXPRESSION; PROGNOSTIC-FACTOR; CELLS; PROGRESSION; HEAD;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Our study was aimed to make sure whether ADAM12 could serve as a prognostic biomarker of estrogen receptor (ER) -positive breast cancer. Methods: 127 patients with ER-positive breast cancer were included in the present study. The level of ADAM12 was assayed through real-time quantitative PCR (RT-qPCR). Levels of ADAM12 in tumor tissues and adjacent normal tissues were compared with paired t-test. The association of ADAM12 expression with clinical characteristics was analyzed via X-2 test. Kaplan-Meier survival curve was used to evaluate the role of ADAM12 expression in overall survival (OS) of patients. Cox-regression analysis was performed to judge if ADAM12 could serve as a prognostic marker in breast cancer. Results: The level of ADAM12 was upregulated in tumor tissues of breast cancer compared to that of adjacent normal tissues (P < 0.05). The expression of ADAM12 was closely related to the Ki-67 and HER2 status (P < 0.05 for both). The results of Kaplan-Meier survival curve showed that patients with higher level of ADAM12 exhibited shorter survival time compared to that of low level of ADAM12 (P < 0.001). Cox regression analysis showed that ADAM12 might be a biomarker in predicting prognosis of patients with ER-positive breast cancer (HR = 7.116, 95% Cl = 3.329-15.212). Conclusion: ADAM12 appears to be a prognostic marker in ER-positive breast cancer.
引用
收藏
页码:13279 / 13283
页数:5
相关论文
共 28 条
  • [1] Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
  • [2] Prognostic value of a 92-probe signature in breast cancer
    Akter, Salima
    Choi, Tae Gyu
    Nguyen, Minh Nam
    Matondo, Abel
    Kim, Jin-Hwan
    Jo, Yong Hwa
    Jo, Ara
    Shahid, Muhammad
    Jun, Dae Young
    Yoo, Ji Youn
    Nguyen, Ngoc Ngo Yen
    Seo, Seong-Wook
    Ali, Liaquat
    Lee, Ju-Seog
    Yoon, Kyung-Sik
    Choe, Wonchae
    Kang, Insug
    Ha, Joohun
    Kim, Jayoung
    Kim, Sung Soo
    [J]. ONCOTARGET, 2015, 6 (17) : 15662 - 15680
  • [3] Molecular Markers for Breast Cancer: Prediction on Tumor Behavior
    Banin Hirata, Bruna Karina
    Maeda Oda, Julie Massayo
    Guembarovski, Roberta Losi
    Ariza, Carolina Batista
    Coral de Oliveira, Carlos Eduardo
    Ehara Watanabe, Maria Angelica
    [J]. DISEASE MARKERS, 2014, 2014
  • [4] The role of protease activity in ErbB biology
    Blobel, Carl R.
    Carpenter, Graham
    Freeman, Matthew
    [J]. EXPERIMENTAL CELL RESEARCH, 2009, 315 (04) : 671 - 682
  • [5] Cadoo KA, 2013, Q J NUCL MED MOL IM, V57, P312
  • [6] Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer
    Cheng, Chee Leong
    Thike, Aye Aye
    Tan, Sie Yong Jane
    Chua, Pei Jou
    Bay, Boon Huat
    Tan, Puay Hoon
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (01) : 99 - 111
  • [7] The ADAMs family of proteases: New biomarkers and therapeutic targets for cancer?
    Duffy M.J.
    Mullooly M.
    O'Donovan N.
    Sukor S.
    Crown J.
    Pierce A.
    McGowan P.M.
    [J]. Clinical Proteomics, 2011, 8 (1)
  • [8] Molecular profiling of ADAM12 in human bladder cancer
    Frohlich, Camilla
    Albrechtsen, Reidar
    Dyrskjot, Lars
    Rudkjaer, Lise
    Orntoft, Torben F.
    Wewer, Ulla M.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (24) : 7359 - 7368
  • [9] ADAM12 Produced by Tumor Cells Rather than Stromal Cells Accelerates Breast Tumor Progression
    Frohlich, Camilla
    Nehammer, Camilla
    Albrechtsen, Reidar
    Kronqvist, Pauliina
    Kveiborg, Marie
    Sehara-Fujisawa, Atsuko
    Mercurio, Arthur M.
    Wewer, Ulla M.
    [J]. MOLECULAR CANCER RESEARCH, 2011, 9 (11) : 1449 - 1461
  • [10] Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer
    Hedau, Suresh
    Batra, Madhu
    Singh, Usha Rani
    Bharti, Alok C.
    Ray, Amitabha
    Das, Bhudev C.
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (01) : 158 - 163